Role of mathematical modeling on the optimal control of HIV-1 pathogenesis

AIChE Journal

Volumn 52, Issue 3, 2006, Pages 856-884

  Joly, Marcel ^a,b   Pinto, Jose M ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PETROBRAS   (Brazil)

^c POLYTECHNIC UNIVERSITY   (United States)

Author keywords

AIDS pathogenesis; Chemotherapy; HAART; HIV 1; Mathematical modeling

Indexed keywords

ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS); AIDS PATHOGENESIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART); HUMAN IMMUNODEFICIENCY VIRUS (HIV);

CHEMOTHERAPY; COMPUTER SIMULATION; DISEASES; IMMUNOLOGY; MOLECULAR BIOLOGY; OPTIMAL CONTROL SYSTEMS; PATIENT TREATMENT;

PATHOLOGY;

CHEMOTHERAPY; COMPUTER SIMULATION; DISEASES; IMMUNOLOGY; MOLECULAR BIOLOGY; OPTIMAL CONTROL SYSTEMS; PATHOLOGY; PATIENT TREATMENT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33645579942     PISSN: 00011541     EISSN: 15475905     Source Type: Journal    
DOI: 10.1002/aic.10716     Document Type: Review

References (187)

1. Wick D, Self SG. Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy. Math Biosci. 2000;165:115-134.
2. Kirschner D, Webb GF. A model for treatment strategy in the chemotherapy of AIDS. Bull Math Biol. 1996;58(2):367-390.
3. Kirschner D, Lenhart S, Serbin S. Optimal control of the chemotherapy of HIV. J Math Biol. 1997;35:775-792.
4. Wein LM, Zenios SA, Nowak MA. Dynamic multidrug therapies for HIV: A control theoretic approach. J Theor Biol. 1997;185:15-29.
5. Wodarz D, Nowak MA. Specific therapy regimes could lead to long-term immunological control of HIV. PNAS-USA. 1999;96(25): 14464-14469.
6. Klatt EC. Pathology of AIDS. Technical Report - Department of Pathology, University of Utah; 2000.
7. Brazilian Department of Health. Recommendations for Antiretroviral Therapy in Adults and Adolescents Infected by HIV: Technical Report - Ministério da Saúde, Brasília-DF, Brazil; 2000.
8. Shafer R. Stanford HIV Drug Resistance Database. Available in: http://hivdb.stanford.edu (accessed in 2003).
9. Joly M. Mathematical modeling and optimal control of dynamic reactive systems. University of São Paulo, São Paulo, Brazil; 2004. Ph.D. Thesis.
10. Kirschner D, Perelson A. A model for the immune system response to HIV: AZT Treatment Studies. In: Mathematical Population Dynamics III. Theory of Epidemics, Arino O, Axelrod D, Kimmel M. eds. Winnipeg, Manitoba, Canada: Wuerz Publishing; 1994:(1)296-301.
11. Kilby JM, Hopkins S, Venetta TM. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4:1302-1307.
12. Bowen EF, Atkins M, Weller IVD, Johnson MA. Current Clinical Treatment of Retroviral Infections. In: Antiviral Chemotherapy, Ed.: Jeffries DJ, De Clercq E, Chichester, UK: John Wiley & Sons; 1995:65-79.
13. Vella S, Galluzzo C, Giannini G, Pirillo MF, Duncan I, Jacobsen H, Andreoni M, Sarmati L, Ercoli L. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ Lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res. 1996;29:91-93.
14. Boucher CAB. Human Immunodeficiency Viruses and Human T-Lymphotropic Viruses. In: Antiviral Agents and Human Viral Diseases. 4th ed. Eds. Galasso GJ, Whitley RJ, Merigan TC. Philadelphia: Lippincott-Raven Publishers; 1997:607-695.
15. Van't Wout AB, Ran LJ, De Jong MD, Bakker M, Van Leeuwen R, Notermans DW, Loeliger AE, de Wolf F, Danner SA, Reiss P, Boucher CAB, Lange JMA, Schuitemaker H. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV variants in individuals receiving didanosine or zidovudine, respectively. J Clin Invest. 1997;100(9):2325-2332.
16. Yoshimura K, Kato R, Yusa K, Kavlick MF, Maroun V, Nguyen A, Mimoto T, Ueno T, Shintani M, Falloon J, Masur H, Hayashi H, Erickson J, Mitsuya H. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. PNAS-USA. 1999;96:8675-8680.
17. Stellbrink H, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries P, Degen O, Eggers C, Petersen H, Haag F, Horst H, Dalhoff K, Möcklinghoff C, Cammack N, Tenner-Racz K, Racz P. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS. 2002;16(11):1479-1487.
18. Tsai WP, Conley SR, Kung HF, Garrity RR, Nara PL. Preliminary in vitro growth cycle and transmission studies of HIV-1 in an autologous primary cell assay of blood-derived macrophages and peripheral blood mononuclear cells. Virology. 1996;226:205-216.
19. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185(4):621-628.
20. Price DA, Goulder PJR, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, Bangham CRM, Phillips RE. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. PNAS-USA. 1997;94:1890-1895.
21. Bermejo M, Martín-Serrano J, Oberlin E, Pedraza M, Serrano A, Santiago B, Caruz A, Loetscher P, Baggiolini M, Arenzana-Seisdedos F, Alcami J. Activation of blood T lymphocytes down regulates CXCR4 expression and interferes with propagation of X4 HIV strains. Eur J Immunol. 1998;28:3192-3204.
22. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang X, Mullins JM. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 1999;73(2):10489-10502.
23. Yi Y, Isaacs SN, Williams DA, Frank I, Schols D, De Clercq E, Kolson DL, Collman RG. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus Type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. J Virol. 1999;73(9):7117-7125.
24. Hu Q, Barry AP, Wang Z, Connolly SM, Peiper SC, Greenberg ML. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J Virol. 2000;74(24):11858-11872.
25. Torre VS, Marozsan AJ, Albright JL, Collins KR, Hartley O, Offord RE, Quiñones-Mateu ME, Arts EJ. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol. 2000;74(10):4868-4876.
26. Shieh B, Liau Y, Hsieh P, Yan Y, Wang S, Li C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Intl Immunol. 2000;12(9):1311-1318.
27. Goulder PJR, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, Addo MM, He S, Mukherjee JS, Phillips MN, Bunce M, Kalams SA, Sekaly RP, Walker BD. Brander C. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Of Experimental Med. 2001;193(2):181-194.
28. Hraba T, Dolezal J. A mathematical model and CD4 lymphocyte dynamics in HIV infection. Emerging Infectious Diseases. 1996;2(4): 299-305.
29. McLean AR, Kirkwood TBL. A model of human immunodeficiency virus infection in T helper cell clones. J Theor Biol 1990;147:177-203.
30. McLean AR, Nowak MA. Models of interactions between HIV and other pathogens. J Theor Biol. 1992;155:69-102.
31. Essunger P, Perelson AS. Modeling HIV infection of CD4+ T-cell subpopulations. J Theor Biol. 1994;170:367-391.
32. McLean AR. Modelling T cell memory. J Theor Biol. 1994;170:63-74.
33. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373(12):123-126.
34. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoefter S, Worgall S, Connor R, Kaner RJ, Fenamore E, Sheridan K, Singh R, Crystal RG. Expression and use of human immunodeficiency virus type 1 coreceptors by human alveolar macrophages. J Virol. 1999;73(7):5865-5874.
35. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 Dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271(15):1582-1586.
36. Nowak MA, Bonhoeffer S, Shaw GM, May RM. Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell populations. J Theor Biosci. 1997;184:203-217.
37. Root-Bernstein RS, Merrill SJ. The necessity of cofactors in the pathogenesis of AIDS: A mathematical model. J Theor Biol. 1997; 187:135-146.
38. Stilianakis NI, Boucher CAB, Jong MD, Leeuwen RV, Schuurman R, Boer RJ. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model. J Virol. 1997a;71(1):161-168.
39. Stilianakis NI, Dietz K, Schenzle D. Analysis of a model for the pathogenesis of AIDS. Math Biosci. 1997b;145:27-46.
40. De Boer RJ, Perelson AS. Target cell limited and immune control models of HIV infection: A comparison. J Theor Biol. 1998;190:201-214.
41. Mittler JE, Sulzer B, Neumann AU, Perelson AS. Influence of delayed viral production on viral dynamics in HIV-1 infected patients. Math Biosci. 1998;152:143-163.
42. Murray JM, Kaufmann G, Kelleher AD, Cooper DA. A model of primary HIV-1 infection. Math Biosci. 1998;154:57-85.
43. Nelson PW. Mathematical Models of HIV Pathogenesis and Immunology. University of Washington, Washington, DC; 1998. PhD Thesis.
44. Tan WY, Wu H. Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies. Math Biosci. 1998;147:173-205.
45. Wein LM, D'Amato RM, Perelson AS. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol. 1998;192:81-98.
46. Ding AA, Wu H. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. Math Biosci. 1999;160:63-82.
47. Perelson AS, Nelson PW. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Review. 1999;41(1):3-44.
48. Tan WY, Xiang Z. Some state space models of HIV pathogenesis under treatment by anti-viral drugs in HIV-infected individuals. Math Biosci. 1999;156:69-94.
49. + T-cell. Math Biosci. 2000;165:27-39.
50. Nelson PW, Murray JD, Perelson AS. A model of HIV-1 pathogenesis that includes an intracellular delay. Math Biosci. 2000;163:201-215.
51. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, Perelson AS. Modeling plasma virus concentration during primary HIV infection. J Theor Biol. 2000;203:285-301.
52. Kamina A, Makuch RW, Zhao H. A stochastic modeling of early HIV-1 population dynamics. Math Biosci. 2001;170:187-198.
53. Bellman R. Dynamic Programming. Princeton: Princeton University Press; 1957.
54. Pontryagin LS, Boltyanskii V, Gamkrelidge R, Mishchenko E. The Mathematical Theory of Optimal Processes. New York: Interscience Publishers Inc.; 1962.
55. Kirk DE. Optimal Control Theory - An Introduction. New Jersey: Prentice-Hall; 1970.
56. Bryson AE, Ho YC. Applied Optimal Control - Optimization, Estimation and Control. New York: Taylor & Francis Inc.; 1981.
57. Marlin TE, Hrymak AN. Real-Time Operations Optimization of Continuous Processes. In: Proc. of Fifth International Conference on Chemical Process Control. Kantor JC, Garcia CE, Carnahan B, Eds. 1997;93(316):156-164.
58. Helbig A, Abel O, Marquardt W. Structural Concepts for Optimization Based Control of Transients Processes. Technical Report LPT-1998-20, Lehrstuhl für Prozesstechnik, Aachen, Germany; 1998.
59. Leineweber DB, Schafer A, Bock HG, Schloder JP. An efficient multiple shooting based reduced SQP strategy for large-scale dynamic process optimization. Comp Chem Eng. 2003;27(2):167-174.
60. Lin JH, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997;49(4):403-449.
61. Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, Simon C, Kline MW. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother. 2000;44(4):1029-1034.
62. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. PNAS USA. 1997;94:1925-1930.
63. + cells: Evidence for HLA class I restricted triggering of cytolitic and noncytolitic mechanisms. J Virol. 1997a; 71(4):3120-3128.
64. Yang OO, Tran A, Kalams SA, Johnson RP, Roberts MR, Walker BD. Lysis of HIV-1 infected cells and inhibition of viral replications by universal receptor T cells. PNAS-USA. 1997b;94:11478-11483.
65. + T lymphocytes through the T cell receptor turns on CD4 gene expression: Implication for HIV pathogenesis. PNAS-USA. 1998;95:3111-3116.
66. Carr JM, Hocking H, Li P, Burrell CJ. Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology. 1999;265:319-329.
67. Hickey WF. The Immunology of the Nervous System. Technical Report: Dartmouth Medical School Hanover, New Hampshire; 1999.
68. + T-cell response: Persisting effectors and resting memory T cells. J Immunol 2001;166:926-935.
69. Farber DL. T cell memory: Heterogeneity and mechanisms. Clin Immunol. 2000;95(3):173-181.
70. Mori K, Yasutomi Y, Sawada S, Villinger F, Sugama K, Rosenwith B, Heeney JL, Überla K, Yamazaki S, Ansari, AA, Rübsamen-Waigmann H. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol. 2000;74(13):5747-5753.
71. + T cell mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. PNAS-USA. 2000;97(7):3503-3508.
72. Sewell AK, Price DA, Oxenius A, Kelleher AD, Phillips RE. Cytotoxic T lymphocyte responses to human immunodeficiency virus: Control and scape. Stem Cells. 2000;18(4):230-244.
73. Chun T, Justement JS, Moir S, Hallahan CW, Ehler LA, Liu S, McLaughlin M, Dybul M, Mican JM, Fauci AS. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: Implications for the development of therapeutic strategies. PNAS-USA. 2001;98(1):253-258.
74. + cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. PNAS-USA. 2001;98(2):597-602.
75. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science. 2001;254:423-426.
76. Fields BN, Knipe DM, Howley PM. Fundamental Virology. 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1996.
77. Cornelissen M, Burg R, Zorgdrager F, Lukashov V, Goudsmit J. Pol gene diversity of five human immunodeficiency virus type 1 sub-types: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol. 1997;71(9):6348-6358.
78. Korber B, Theiler J, Wolinsky S. Limitations of a molecular clock applied to considerations of the origin of HIV-1. Science. 1998;280:1868-1871.
79. Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, Miller V, Sturmer M, Staszewski S, Ren J, Stammers DK, Stuart DI, Pauwels R. A family of insertion mutations between Codons 67 e 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother. 1999;43(8):1961-1967.
80. Frost SDW, Dumaurier M, Wain-Hobson S, Brown AJL. Genetic drift and within-host metapopulation dynamics of HIV-1 infection. PNAS-USA. 2001;98(12):6975-6980.
81. Gorshkova II, Rausch JW, Le Grice SFJ, Crouch RJ. HIV-1 reverse transcriptase interaction with model RNA-DNA duplexes. Anal Biochem. 2001;291:198-206.
82. Lennerstrand J, Stammers DK, Larder BA. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob Agents Chemother. 2001;45(7):2144-2146.
83. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995;69(8):5087-5094.
84. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology. 4th ed. Philadelphia: W.B. Saunders Company; 2000.
85. Flint SJ, Enquist LW, Krug RM, Racaniello VR, Skalka AM. Principles of Virology - Molecular Biology, Pathogenesis, and Control. Washington: ASM Press; 2000.
86. García-Lerma JG, Gerrish PJ, Wright AC, Qari SH, Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J Virol. 2000;74(20):9339-9346.
87. + T cells during human endotoxemia and after stimulation with (Myco) bacterial antigens: The role of cytokines. Blood. 2000;96(8):2649-2654.
88. Viswanathan J, Grossmann IE. A combined penalty function and outer approximation method for MINLP optimization. Comp Chem Eng. 1990;14(7):769-782.
89. IBM. OSL (Optimization Subroutine Library) Guide and Reference - release 2. New York: Kingston; 1991.
90. Drud AS. A System for Large Scale Nonlinear Optimization, Reference Manual for Conopt Subroutine Library. Bagsvaerd, Denmark: ARKI Cons. & Develop. A/S; 1996.
91. Ito S. Numerical methods of nonlinear optimal control based on mathematical programming. Nonlinear Anal Theory Meth and Appl. 1997;30(6):3843-3854.
92. Brooke A, Kendrick D, Meeraus A, Raman R. GAMS - A User's Guide. Washington, DC: GAMS Development Corp.; 1998.
93. ILOG Inc. ILOG Solver 4.4 - User's Manual; 1999.
94. Bisschop J, Roelofs M. AIMMS - The User's Guide. Haarlem, The Netherlands: Paragon Decision Technology B.V.; 2004.
95. Müller V, Marée AFM, De Boer RJ. Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood. J Virol. 2001;75(6):2597-2603.
96. Goldstein H, Pettoello-Mantovani M, Katopodis NF, Kim A, Yurasov S, Kollmann TR. SCID-hu mice: A model for studying disseminated HIV infection. Immunology. 1996;8:223-231.
97. Ho DD. Dynamics of HIV-1 replication in vivo. J Clin Invest. 1997;99(11):2565-2567.
98. Gupta P, Balachandran R, Ho M, Enrico A, Rinaldo C. Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. J Virol. 1989;63(5):2361-2365.
99. Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, Fauci AS. Lymphoid organs function as major reservoirs for human immunodeficiency virus. PNAS-USA. 1991;88:9838-9842.
100. Ho DD. Viral counts count in HIV infection. Science. 1996;272:1124-1125.
101. + T lymphocytes. PNAS-USA. 2000;97(7):3382-3387.
102. Gummuluru S, Kinsey CM, Emerman M. An in-vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol. 2000;74(23):10882-10891.
103. + T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood. 2001;98(1):156-164.
104. + T-cell effector activity in HIV primary infection. J Clin Invest. 1999;104(10):1431-1439.
105. Grossman Z, Fejnberg MB, Paul WE. Multiple modes of cellular activation and virus transmission in HIV infection: A role for chronically and latently infected cells in sustaining viral replication. Immunology. 1998;95(11):6314- 6319.
106. Nowak MA, Anderson RM, Boerlijst MC, Bonhoeffer S, May RM. HIV-1 evolution and disease progression. Science. 1996;74(8):1008-1011.
107. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-358.
108. Van't Wout AB, Ran LJ, Kuiken CL, Kooststra NA, Pals ST, Schuitemaker H. Analysis of the temporal relationship between human immunodeficiency virus Type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J Virol. 1998;72(1):488-496.
109. Duesberg P. HIV is not the cause of AIDS. Science. 1998;241:514-517.
110. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387(8):188-191.
111. Albright AV, Shieh JTC, Itoh T, Lee B, Pleasure D, O'Connor MJ, Doms RW, González-Scarano F. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol. 1999;73(1):202-213.
112. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocite subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. PNAS-USA. 1999;96:5215-5220.
113. Kepler TB, Perelson AS. Drug concentration heterogeneity facilitates the evolution of drug resistance. PNAS-USA. 1998;95:11514-11519.
114. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998;72(4):2855-2864.
115. Lee S, Lapham CK, Chen H, King L, Manischewitz J, Romantseva T, Mostowski H, Stantchev TS, Broder CC, Golding H. Coreceptor competition for association with CD4 may change the susceptibility of human immunodeficiency virus type 1. J Virol. 2000;74(11):5016-5023.
116. Wu BL, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA, Mackay CR. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997;185(9):1681-1691.
117. Rucker J. Edinger AL, Sharron M, Samson M, Lee B, Berson JF, Yi Y, Margulies B, Collmann RG, Doranz BJ, Parmentier M, Doms RW. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol. 1997;71(12):8999- 9007.
118. + lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol. 1998;72(11):9054-9060.
119. Moriuchi M, Moriuchi H, Turner W, Fauci AS. Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1. J Clin Invest. 1998;102(8):1540-1550.
120. + T lymphocytes. Blood. 2000;96(5):1853-1856.
121. Philpott S, Weiser B, Anastos K, Kitchen CMR, Robison E, Meyer III WA, Sacks HS, Mathur-Wagh U, Brunner C, Burger H. Preferential suppression of CXCR4 specific strains of HIV-1 by antiviral therapy. J Clin Invest. 2001;107(4):431-438.
122. + T cells. J Immunol. 2000;164:4018-4024.
123. Singh A, Collman RG. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies. J Virol. 2000;74(21):10229-10235.
124. Hariharan D, Douglas SD, Lee B, Lai J, Campbell DE, Ho W. Interferon-γ upregulates CCR5 expiession in cord and adult blood mononuclear phagocytes. Blood. 1999;93(4):1137-1144.
125. Tuttle DL, Harrison JK, Anders C, Sleasman JW, Goodenow MM. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J Virol. 1998;72(6):4962-4969.
126. Ostrowski MA, Justement SJ, Catanzaro A, Hallahan CA, Ehler LA, Mizell SB, Kumar PN, Mican JA, Chun T, Fauci AS. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and un-infected individuals. J Immunol. 1998;161:3195-3201.
127. Rabin RL, Park MK, Liao F, Swofford R, Stephany D, Farber JM. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol. 1999;162:3840-3850.
128. Hornung F, Scala G, Lenardo MJ. TNF-α-induced secretion of C-C chemokines modulates C-C chemokine receptor 5 expression on peripheral blood lymphocytes. J Immunol. 2000;164:6180-6187.
129. Ebert LM, McColl SR. Coregulation of CXC chemokine receptor and CD4 expression on T lymphocytes during allogeneic activation. J Immunol. 2001;166:4870-4878.
130. Naif HM, Li S, Alali M, Sloane A, Wu L, Kelly M, Lynch G, Lloyd A, Cunningham AL. CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol. 1998;72(1):830-836.
131. Sozzani S, Ghezzi S, Iannolo G, Luini W, Borsatti A, Polentarutti N, Sica A, Locati M, Mackay C, Wells TNC, Biswas P, Vicenzi E, Poli G, Mantovani A. Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med. 1998;187(3):439-444.
132. Worgall S, Connor R, Kaner RJ, Fenamore E, Sheridan K, Singh R, Crystal RG. Expression and use of human immunodeficiency virus type 1 coreceptors by human alveolar macrophages. J Virol. 1999; 73(7):5865-5874.
133. Esté JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, Clotet B, Schols D, De Clercq E. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol. 1999;73(7):5577-5585.
134. Joly M, Pinto JM. CXCR4 and CCR5 regulation and expression patterns on T- and monocyte-macrophage cell lineages: Implications for susceptibility to infection by HIV-1. Math Biosc. 2005:195:92-126.
135. Berkowitz RD, Van't Wout AB, Koostra NA, Moreno ME, Linquist-Stepps VD, Bare C, Stoddart CA, Shuitemaker H, McCune JM. R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not posses X4-type pathogenicity in human thymus. J Virol. 1999;73:7817-7822.
136. Unutmaz D, Littman DR. Expression pattern of HIV-1 coreceptors on T cells: Implications for viral transmission and lymphocyte homing. PNAS-USA. 1997;94:1615-1618.
137. Schuitemaker H, Koot M, Koostra NA, Dercksen MW, Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol. 1992;66(3):1354-1360.
138. Wodarz D, Lloyd AL, Jansen VAA, Nowak MA. Dynamics of macrophage and T cell infection by HIV. J Theor Biol. 1999a;196:101-113.
139. + T cell decline. PNAS-USA. 2000;97(3):1269-1274.
140. Jamieson BD, Aldrovandi GM, Zack JA. The SCID-hu mouse: An in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS. Immunology. 1996;8:215-221.
141. Bonyhadi ML, Rabin L, Salimi S, Brown DA, Kosek J, McCune JM, Kaneshima H. HIV induces thymus depletion in vivo. Nature. 1993;363:728-732.
142. Chun T, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. PNAS-USA. 1997b;94:13193-13197.
143. Badley AD, Pilon AA, Landay A, Lynch DH. Mechanisms of HIV-associated lymphocyte apoptosis. Blood. 2000;96(9):2951-2964.
144. Bartz SR, Emerman M. Human immunodeficiency virus type 1 tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/Caspase-8. J Virol. 1999;73(3):1956-1963.
145. + T cells are infectible by human immunodeficiency virus but do not release virus after activation. J Virol. 1995;69(9):5659-5665.
146. St Luce S, Arts E, Geleziunas R, Bour S, Weinberg MA. Infection of human monocyte-derived macrophages by human immunodeficiency virus mediated by cell-to-cell transmission. J Med Virol. 1993;41:71-78.
147. Cossarizza A, Mussini C, Borghi V, Mongiardo N, Nuzzo C, Pedrazzi J, Benatti F, Moretti L, Pinti M, Paganelli R, Franceschi C, De Rienzo B. Apoptotic features of peripheral blood granulocytes and monocytes during primary, acute HIV infection. Exp Cell Res. 1999;247:304-311.
148. + T Lymphocytes Results in Altered T Cell Responses with Enhanced Production of IFN-γ and IL-10. Virology. 1996;215:51-60.
149. Phillips AN. Reduction of HIV concentration during acute infection: Independence from a specific immune response. Science. 1996;271:497-499.
150. Spouge JL, Shrager RI, Dimitrov DS. HIV-1 infection kinetics in tissue cultures. Math Biosci. 1996;138:1-22.
151. Tuckwell HC, Le Corfec E. A stochastic model for early HIV-1 population dynamics. J Theor Biol. 1998;195:451-463.
152. Soudeyns H, Campi G, Rizzardi GP, Lenge C, Demarest JF, Tambussi G, Lazzarin A, Kaufmann D, Casorati G, Corey L, Pantaleo G. Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor β chain repertoire and reduces the level of T-cell oligoclonality. Blood. 2000;95(5):1743-1751.
153. De Boer RJ, Boucher CAB. Anti-CD4 therapy for AIDS suggested by mathematical models. Proc Roy Soc London B. 1996;263:899-905.
154. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med. 1998; 188(12):2199-2204.
155. Wodarz D, Nowak MA, Bangham CRM. The dynamics of HTLV-1 and the CTL response. Immunology Today. 1999b;20(5):220-227.
156. + T lymphocytes by HIV-1. J Exp Med. 1998;187(7):1139-1144.
157. Rinaldo C, Huang X, Fan Z, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M, Gupta P. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol. 1995;69(9):5838-5842.
158. Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lifton MA, Lord CI, Forman MA, Letvin NL. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol. 1999;162:5127-5133.
159. Chen H, Yip YK, George I, Tyorkin M, Salik E, Sperber K. Chronically HIV-1-monocytic cells induce apoptosis in cocultured T cells. J Immunol. 1998;161:4257-4267.
160. Ferris RL, Hall C, Sipsas NV, Safrit JT, Trocha A, Koup RA, Johnson RP, Siliciano RF. Processing of HIV-1 envelope glyprotein for class I-restricted recognition: Dependence on TAP1/2 and mechanisms for cytosolic localization. J Immunol. 1999;162:1324-1332.
161. López D, Gil-Torregrosa BC, Bergmann C, Del Val M. Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1
162. + T lymphocytes, monocytes, and dendritic cells by cytotoxic T lymphocytes. J Virol. 2000;74(14):6695-6699.
163. Kmieciak D, Wasik TJ, Teppler H, Pientka J, Hsu SH, Takahashi H, Okumura K, Kaneko Y, Kozbor D. The effect of deletion of the V3 loop of Gp120 on cytotoxic T-cell responses and HIV Gp120-mediated pathogenesis. J Immunol. 1998;160:5676-5683.
164. Anderson RM. Mathematical and statistical studies of the epidemiology of HIV. AIDS. 1989;3:333-346.
165. Perelson AS. Modeling the interaction of the immune system with HIV. In: Mathematical and Statistical Approaches to AIDS Epidemiology. C. Castillo-Chavez, Ed. Lecture Notes Biomath. New York: Springer; 1989;83:350-352.
166. Papamichail I, Adjiman CS. Global optimization of dynamic systems. Comp Chem Eng. 2004;28(3):403-415.
167. Reibnegger G, Fuchs D, Hausen A, Werner ER, Werner-Felmayer G, Dierich MP, Watcher H. Stability analysis of simple models for immune cells interacting with normal pathogenesis and immune system retroviruses. Proc Natn Acad Sci USA. 1989;86:2026-2030.
168. + lymphocyte count in non-progressors and progressors toward AIDS. Clin Exp Immunol. 1990;81:177-182.
169. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM, Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373(12):117-122.
170. Virco BVBA. The Virtual Phenotype™. Available in: www.virco-lab.com/web/page.asp?id=83&page_id=161 (accessed in 2002).
171. Jong MD, Veenstra J, Stilianakis NI, Schuurman R, Lange JMA, Boer RJ, Boucher CAB. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. PNAS-USA. 1996;93:5501-5506.
172. Garey MR, Johnson DS. Computers and Intractability - A Guide to the Theory of NP-Completeness. New York: Freeman and Co.; 1979.
173. Gunaratna C. Drug metabolism and pharmacokinetics in drug discovery: A primer for bioanalytical chemists, Part II. Current Separations. 2001;19(3):87-92.
174. The Body Health Resources Corporation. Drug Side Effects Chart. Available in: http://www.thebody.com/pinf/sideeffectchart.html (accessed in 2001).
175. Vavasis S. Nonlinear Optimization: Complexity Issues. New York: Oxford University Press; 1991.
176. Joly M, Pinto JM. Pharmacogenomic mixed integer dynamic optimization model for viral dynamics in HIV-1/AIDS infection. Part I. Primary (Acute) Infection. In: AIChE Annual Meeting, Indianapolis: November 3-7; 2002.
177. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-1295.
178. + T cells in chronic human immunodeficiency virus infection. Blood. 2000;96(9):3094-3101.
179. Monteiro LHA, Gonçalves CHO, Piqueira JRC. A condition for successful escape of a mutant after primary HIV infection. J Theor Biol. 2000;203:399-406.
180. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, Martin MA. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol. 1998;72:2509-2515.
181. Merrill SJ. Modeling the interaction of HIV with cells of the immune system. Lect Notes Biomath. 1989;83:371.
182. Nowak MA. Variability of HIV infections. J Theor Biol 1992;155:1-20.
183. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68(7):4650-4655.
184. Agur Z. A new method for reducing cytotoxicity of the anti-AIDS drug AZT. In: Biomedical Modeling and Simulation. DS Levine, Ed. Scientific Publishing; 1989:59-61.
185. Cojocaru L, Agur Z. A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math Biosci. 1992;109:85-97.
186. Loveday C, Kaye S, Tenant-Flowers M, Semple M, Ayliffe U, Weller IVD, Tedder RS. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet. 1995;345:820-824.
187. McLean AR, Frost SDW. Zidovudine and HIV: Mathematical models of within-host population dynamics. Rev Med Virol. 1995;5:141-147.